doi: 10.1002/prca.201600169 60 HeLWongCKCheungKKYauHCFuAZhaoHLet al
If you're experiencing concerning symptoms or need guidance on treatment options, Doctronic can help you determine the right level of care
What clinical trials tell us The evidence base sits with the compounds, not the payment model
News provided by Eli Lilly and Company Jul 23, 2026, 06:45 ET In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist
Citations Please use one of the following formats to cite this article in your essay, paper or report: APA Chaphalkar, Sushama R
&srotate=0)
